Oncolytics Biotech Inc. filed its Form 10-Q with the U.S. Securities and Exchange Commission on November 13, 2026, reporting financial results for the quarterly period ended September 30, 2026.

Key Highlights

  • Net loss for nine months: The company reported a net loss of $28,390 thousand for the nine months ended September 30, 2026, compared to $19,866 thousand for the same period in 2025.
  • Net loss for Q3 2026: Net loss for the three months ended September 30, 2026 was $9,705 thousand, versus $9,878 thousand in Q3 2025.
  • Cash position: Cash and cash equivalents totaled $2,430 thousand as of September 30, 2026, down from $5,202 thousand at December 31, 2025.
  • Stockholders' deficit: Total stockholders' deficit was $(7,503) thousand at September 30, 2026, compared to $(3,799) thousand at December 31, 2025.
  • Shares outstanding: As of November 13, 2026, the company had 136,140,469 common shares outstanding; 132,207,168 shares were issued and outstanding as of September 30, 2026.
  • Total liabilities: Total liabilities increased to $13,335 thousand from $11,381 thousand at December 31, 2025, with a new stock option liability of $2,233 thousand appearing on the balance sheet.

Oncolytics Biotech's Financial Position Through September 30, 2026

According to the filing, Oncolytics Biotech Inc. (NASDAQ:ONCY) reported total operating expenses of $28,402 thousand for the nine months ended September 30, 2026, compared to $19,235 thousand in the same period of 2025. Research and development expenses were $13,966 thousand and general and administrative expenses were $14,436 thousand for the nine-month period. For the three months ended September 30, 2026, total operating expenses were $9,742 thousand, up from $9,563 thousand in Q3 2025.

The company disclosed a loss from operations of $28,402 thousand for the nine months ended September 30, 2026. Total other income, net, was $100 thousand for the nine-month period, primarily from interest income of $100 thousand. The basic and diluted net loss per share was $(0.24) for the nine months ended September 30, 2026, compared to $(0.22) for the same period in 2025. For Q3 2026 alone, the loss per share was $(0.08), based on a weighted average of 127,892,383 common shares outstanding.

The balance sheet as of September 30, 2026 showed total assets of $5,832 thousand and total liabilities of $13,335 thousand, resulting in a total stockholders' deficit of $(7,503) thousand. The accumulated deficit stood at $(457,885) thousand as of September 30, 2026, compared to $(429,495) thousand at December 31, 2025. A new stock option liability of $2,233 thousand was reported as of September 30, 2026, where none existed at December 31, 2025. The contract liability of $4,910 thousand remained unchanged from year-end. The company is classified as a non-accelerated filer and smaller reporting company. The filing notes that forward-looking statements are subject to various risks and uncertainties, as described further under "Item 1A. Risk Factors."

What Was Disclosed

Oncolytics Biotech filed its quarterly report covering the period ended September 30, 2026, disclosing a nine-month net loss of $28,390 thousand, cash of $2,430 thousand, a total stockholders' deficit of $(7,503) thousand, and 136,140,469 common shares outstanding as of November 13, 2026.